PRP vs Corticosteroid Injection for Runners’ Tendinopathy: Sprint now or build for the long haul? | A systematic review and meta‐analysis | Find Your Stride | Edinburgh Podiatrist
- Joshua Francois
- 5 days ago
- 4 min read
Should we be using injections for Tendinopathy?
This 2025 systematic review and meta-analysis synthesises 27 randomised controlled trials (n=1,779) comparing platelet‑rich plasma (PRP) with corticosteroid (CS) injections across four conditions: rotator cuff tendinopathy, lateral epicondylitis, plantar fasciitis, and tenosynovitis. For clinicians counseling runners and field-sport athletes, two themes matter: the time course of benefit and whether improvements translate to function that supports return to sport.
What the meta-analysis reports
Rotator cuff tendinopathy:
No between-group differences at 1 month for pain or function.
At 3 months, PRP showed greater pain reduction than CS; shoulder-specific function differences were not significant at 3–6 months.
Plantar fasciitis:
No differences at 1–3 months in pain (VAS) or AOFAS.
At 6 months, PRP outperformed CS on both pain and AOFAS.
Lateral epicondylitis:
CS showed better early function (about 1 month).
PRP surpassed CS on pain and DASH at 3 and 12 months.
Tenosynovitis:
CS favored at 1 month (lower VAS).
PRP favored at 6 months (lower VAS).
Adverse events were infrequently reported and generally low, but study quality limitations (unclear allocation concealment, blinding issues, small samples) temper confidence.
Strengths
Broad, multi-condition scope with exclusively randomised trials.
Clear, clinically relevant time-binning: early (≤1 month), mid-term (3–6 months), long-term (>6 months).
Inclusion of plantar fasciitis—a high-yield condition for podiatry and running populations.
Limitations that matter in sport
Heterogeneity is high:
PRP protocols varied (leukocyte-rich vs poor, activation methods, volume, single vs series).
Steroid types, doses, and injection guidance differed.
Outcome measures were not uniform (VAS, AOFAS, DASH, disease-specific scores), constraining pooled inference.
Functional/return-to-sport (RTS) metrics are scarce:
Few trials linked symptom change to running tolerance, loading progression, or performance tasks.
Follow-up windows often stop where athletes still care:
Mid-term signals favor PRP, but long-term durability and re-injury/relapse rates remain under-characterised.
Risk-of-bias concerns:
Many trials had unclear or high risk in at least one domain; small samples reduce precision and raise publication-bias suspicions.
What this means for runners and clinicians
Steroid = fast pain relief, fragile durability:
Useful for short-term symptom suppression (weeks) when a near-term competition or graded loading test is needed.
Risk of symptom rebound and potential tendon compromise with repeated doses remains a concern in high-load athletes.
PRP = slower onset, stronger mid-term signal:
Plantar fasciitis, lateral epicondylitis, and rotator cuff pain show better outcomes for PRP from 3–6 months onward.
This aligns with biological plausibility (tendon remodeling needs time) and supports PRP as a “build capacity” option rather than a race-week fix.
Expectation-setting by condition and timeline
Plantar fasciitis:
0–3 months: PRP ≈ CS on average; plan symptom management and loading structure.
~6 months: PRP advantages in pain and AOFAS; pair with progressive calf-plantar fascia loading, rocker footwear trials, and mileage ramp.
Lateral epicondylitis:
Early: CS may help function briefly.
3–12 months: PRP wins on pain and DASH; for racquet/throwing sport cross-trainers, consider PRP when timeline allows.
Rotator cuff tendinopathy:
Mid-term pain benefit with PRP; function parity suggests rehab quality will dictate RTS more than injectate choice.
Tenosynovitis:
Early CS advantage; mid-term PRP advantage. Choose based on athlete schedule and tolerance for delayed benefit.
Practical decision guide for sport timelines
Racing within 4–6 weeks:
Consider CS only as part of a tightly controlled plan with immediate load audit, gait adjustments, and a hard cap on intensity; avoid repeat CS cycles.
Building for a season (8–24 weeks):
Consider PRP, especially for plantar fasciitis and lateral epicondylitis, with an explicit 12–16 week horizon for benefit.
Regardless of injectate:
Anchor to progressive loading protocols (isometrics → isotonic heavy-slow resistance → energy-storage and release), run-program manipulation (cut stride length, control downhill, increase cadence), and footwear/orthoses interventions suited to the tendon condition.
Track response with objective markers: 24–48 h pain echo, hop tolerance, single-leg calf capacity, morning pain for PF, and graded return-to-run tests.
Safety and ethics in an athletic context
Minimise repeat steroid exposure to reduce potential tendon and soft-tissue adverse effects; use image guidance where anatomic accuracy impacts outcomes.
Be transparent about PRP variability (preparation, dose, activation) and out-of-pocket costs; “PRP” is not a single product.
Neither injectate substitutes for strength and tissue capacity; injections should unlock adherence to a progressive plan, not replace it.
Research gaps that would help sport decisions
Standardised PRP protocols (LR vs LP, volume, activation) and dose–response studies.
Trials powered for athlete-relevant RTS outcomes and workload metrics, not only symptom scales.
Longer-term follow-up (12–24 months) capturing relapse, additional interventions, and training load sustainability.
Cost-effectiveness in working-age, sport-participating populations.
Bottom line
For runners and active patients with plantar fasciitis, lateral epicondylitis, or rotator cuff symptoms, PRP tends to outperform corticosteroids from 3–6 months onward; steroids may offer earlier relief but fade.
Choose the injectate to match the goal: CS for a narrow short-term window with caution; PRP for mid-term, capacity-building trajectories—always within a structured, progressive loading plan that drives return to running.
Find Your Stride!
Citation
Ye Z, Yuan Y, Kuang G, Qiu L, Tan X, Wen Z, Lu M. Platelet-rich plasma and corticosteroid injection for tendinopathy: a systematic review and meta-analysis. BMC Musculoskeletal Disorders. 2025;26:339. doi:10.1186/s12891-025-08566-3. Open Access.